{"prompt": "['Novartis', 'Confidential', 'Page 43', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', 'Follow-', 'Period', 'Screen', 'Placebo Run-in', 'Treatment', 'Notes', 'up', 'Visit Number (Site visits)', '1', '101', '199', '201', '202', '203', '204', 'TD', '299', '301', 'Follow-up Visit 301 is only applicable for', 'patients not participating in the safety study.', 'Visit 199 and Visit 201 occur on the same', 'Treatment Week', '-3', '-1', '0', '0', '2', '4', '8', 'TD', '12', '16', 'day.', 'Treatment Day', '-21', '-7', '1', '1', '14', '28', '56', '84', '112', 'negative. If positive, the patient must be', 'discontinued from study drug.', 'Urinalysis and urine chemistry', 'X', 'X', 'X', '(central laboratory)', 'Blood sample for hematology', 'and chemistry (central', 'X', 'X', 'X', 'X', 'No fasting requirement prior to blood', 'laboratory)', 'sampling.', 'Blood sample for', 'RAST/ImmunoCAP test', 'X', '(central laboratory)', 'If results for chemistry, hematology, HbA1c,', 'Review Visit 1 laboratory results', 'S', 'RAST/ImmunoCAP, urine chemistry and', 'urinalysis are missing, obtain a repeat for the', 'missing result.', 'Only if required by health authority and/or', 'Parasitic screening', 'S', 'ethics committee/ institutional review board.', 'Sites should use local laboratories.', 'Spirometry (centralized)', 'X', '1st Pre-dose Spirometry', 'To be performed approximately 45 min. prior', '(centralized) approximately - 45', 'X', 'X', 'X', 'X', 'X', 'to in-clinic witnessed study drug', 'min. pre-dose', 'administration.', '2nd pre-dose Spirometry', 'To be performed approximately 15 min. prior', '(centralized) approximately -15', 'X', 'X', 'X', 'to in-clinic witnessed study drug', 'min. pre-dose', 'administration.']['Novartis', 'Confidential', 'Page 44', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', 'Follow-', 'Period', 'Screen', 'Placebo Run-in', 'Treatment', 'Notes', 'up', 'Visit Number (Site visits)', '1', '101', '199', '201', '202', '203', '204', 'TD', '299', '301', 'Follow-up Visit 301 is only applicable for', 'patients not participating in the safety study.', 'Visit 199 and Visit 201 occur on the same', 'Treatment Week', '-3', '-1', '0', '0', '2', '4', '8', 'TD', '12', '16', 'day.', 'Treatment Day', '-21', '-7', '1', '1', '14', '28', '56', '84', '112', 'ETO be performed prior to reversibility test.', '\"To be performed prior to in-clinic witnessed', 'study drug administration.', 'BTo be performed after the second (-15 min.)', 'Reversibility test (spirometry', 'pre-dose spirometry (may be performed after', 'after administration of short-', 'X**', 'Xa,B *', '10 AM + 1 h).', 'acting \u00df-agonist [SABA])', '**If reversibility is NOT demonstrated at', 'Visit 1, reversibility will be attempted at', 'Visit 101. If not achieved, then one', 'additional attempt allowed within 4 days', 'following Visit 101.', 'Review Visit 1 or Visit 101 or', 'the one additional attempt', 'S', 'reversibility result from overread', 'In case of an asthma exacerbation, the', 'patient should be encouraged by the site to', 'Asthma exacerbation monitoring', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'contact it for advice. If necessary, an', 'unscheduled visit to the site may be', 'arranged.', 'Serious adverse event', 'X', 'X', 'monitoring', 'Adverse event monitoring', 'X', 'X', 'If applicable, review lab results and clinical', 'Liver event monitoring', 'events as per Section 7.3.', 'If applicable, review lab results as per Section', 'Renal event monitoring', 'X', '7.4.']\n\n###\n\n", "completion": "END"}